Phase 3 Readout

HRTX: Phase 3 Topline: A Multicenter, Open-Label, Randomized, Controlled Study to Assess the Antitumor Activity of LNS8801

Name: Phase 3 Topline: A Multicenter, Open-Label, Randomized, Controlled Study to Assess the Antitumor Activity of LNS8801
Start: 2031-02-01
End: 2031-02-01

February 1, 2031. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date: February 1, 2031
Company: HERON THERAPEUTICS, INC. /DE/ (HRTX)

BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 3 Readout~month

Phase 3 Topline: A Multicenter, Open-Label, Randomized, Controlled Study to Assess the Antitumor Activity of LNS8801

February 1, 2031

HRTX overview →

Company: HERON THERAPEUTICS, INC. /DE/ (HRTX)
Indication: Melanoma (Skin Cancer); Melanoma Stage IIIB-IV; Cutaneous Melanoma